CL2018003511A1 - Derivados de pirazolopirimidina como inhibidor de quinasa. - Google Patents
Derivados de pirazolopirimidina como inhibidor de quinasa.Info
- Publication number
- CL2018003511A1 CL2018003511A1 CL2018003511A CL2018003511A CL2018003511A1 CL 2018003511 A1 CL2018003511 A1 CL 2018003511A1 CL 2018003511 A CL2018003511 A CL 2018003511A CL 2018003511 A CL2018003511 A CL 2018003511A CL 2018003511 A1 CL2018003511 A1 CL 2018003511A1
- Authority
- CL
- Chile
- Prior art keywords
- kinase inhibitor
- pyrazolopyrimidine derivatives
- pyrazolopyrimidine
- derivatives
- pirazolopirimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN DERIVADO DE PIRAZOLOPIRIMIDINA, O A UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO. EL COMPUESTO SEGÚN LA PRESENTE INVENCIÓN PUEDE USARSE DE MANERA ÚTIL PARA LA PREVENCIÓN O EL TRATAMIENTO DE ENFERMEDADES QUE ESTÁN ASOCIADOS CON ACCIONES INHIBIDORAS DE QUINASAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160083050 | 2016-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003511A1 true CL2018003511A1 (es) | 2019-04-05 |
Family
ID=60785389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003511A CL2018003511A1 (es) | 2016-06-30 | 2018-12-07 | Derivados de pirazolopirimidina como inhibidor de quinasa. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10961247B2 (es) |
| EP (3) | EP3950691A1 (es) |
| JP (2) | JP2019519579A (es) |
| KR (1) | KR102329162B1 (es) |
| CN (2) | CN113135920A (es) |
| AU (1) | AU2017287762C1 (es) |
| BR (1) | BR112018074621B1 (es) |
| CA (1) | CA3025636C (es) |
| CL (1) | CL2018003511A1 (es) |
| CO (1) | CO2018013293A2 (es) |
| DO (1) | DOP2018000275A (es) |
| EC (1) | ECSP18093777A (es) |
| ES (1) | ES2977557T3 (es) |
| IL (1) | IL263306B (es) |
| MX (2) | MX393499B (es) |
| MY (1) | MY191110A (es) |
| PE (1) | PE20190811A1 (es) |
| PH (1) | PH12018502507B1 (es) |
| RU (1) | RU2714206C1 (es) |
| SA (2) | SA518400547B1 (es) |
| SG (1) | SG11201811470PA (es) |
| WO (1) | WO2018004306A1 (es) |
| ZA (1) | ZA201808431B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11339167B2 (en) | 2017-12-28 | 2022-05-24 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201920150A (zh) | 2017-08-01 | 2019-06-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak激酶抑制劑之吡唑并及三唑并雙環化合物 |
| KR102577241B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| CN108586341B (zh) * | 2018-05-25 | 2020-05-08 | 天津商业大学 | 酰胺类化合物和其药用盐及其制备方法和药物用途 |
| CN119080779A (zh) * | 2018-08-10 | 2024-12-06 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| CN113498352A (zh) | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| CA3109765A1 (en) * | 2019-03-18 | 2020-09-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
| WO2021147952A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| CN115244055B (zh) * | 2020-01-21 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并五元环类衍生物及其应用 |
| CN111620878A (zh) * | 2020-06-10 | 2020-09-04 | 中国药科大学 | 吡咯并嘧啶类衍生物作为蛋白激酶抑制剂及其应用 |
| WO2022002118A1 (zh) * | 2020-07-01 | 2022-01-06 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| WO2022062601A1 (zh) * | 2020-09-22 | 2022-03-31 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| CN114315838B (zh) * | 2020-09-30 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114907357A (zh) * | 2021-02-07 | 2022-08-16 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| EP4540226A1 (en) * | 2022-06-16 | 2025-04-23 | Amphista Therapeutics Ltd | Bifunctional molecules for targeted protein degradation |
| CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
| JP7426544B1 (ja) * | 2022-11-28 | 2024-02-01 | 楽天グループ株式会社 | 画像処理システム、画像処理方法、及びプログラム |
| AU2024266528A1 (en) * | 2023-05-04 | 2025-10-16 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic amine derivatives and pharmaceutical composition comprising same |
| WO2025121899A1 (ko) * | 2023-12-05 | 2025-06-12 | 주식회사 대웅제약 | 1-((3s,4r)-3-((2-((1-에틸-1h-피라졸-4-일)아미노)-7h-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의 제조 방법, 및 이의 중간체 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| MXPA04009243A (es) | 2002-04-12 | 2005-06-08 | Pfizer | Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6. |
| KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
| KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| WO2009026107A1 (en) * | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| WO2009054941A1 (en) | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
| US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| WO2011068899A1 (en) | 2009-12-01 | 2011-06-09 | Abbott Laboratories | Novel tricyclic compounds |
| CA2803056C (en) * | 2010-06-23 | 2017-05-16 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| ES2633793T3 (es) | 2011-09-22 | 2017-09-25 | Merck Sharp & Dohme Corp. | Pirazol carboxamidas como inhibidores de quinasa Janus |
| AU2013204563B2 (en) * | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP2016513621A (ja) | 2013-03-05 | 2016-05-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼの阻害剤 |
| AU2014287016B2 (en) | 2013-07-11 | 2018-11-01 | Acea Biosciences Inc. | Pyrimidine derivatives as kinase inhibitors |
| CN104311573B (zh) * | 2013-09-18 | 2017-12-15 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| NZ720092A (en) | 2013-12-05 | 2019-05-31 | Pfizer | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| CN105777756B (zh) * | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| KR101710127B1 (ko) | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
-
2017
- 2017-06-30 US US16/304,798 patent/US10961247B2/en active Active
- 2017-06-30 MX MX2021009378A patent/MX393499B/es unknown
- 2017-06-30 EP EP21190933.8A patent/EP3950691A1/en active Pending
- 2017-06-30 ES ES17820582T patent/ES2977557T3/es active Active
- 2017-06-30 MY MYPI2018002167A patent/MY191110A/en unknown
- 2017-06-30 SG SG11201811470PA patent/SG11201811470PA/en unknown
- 2017-06-30 RU RU2019102376A patent/RU2714206C1/ru active
- 2017-06-30 EP EP25207256.6A patent/EP4656249A3/en active Pending
- 2017-06-30 AU AU2017287762A patent/AU2017287762C1/en active Active
- 2017-06-30 JP JP2018568407A patent/JP2019519579A/ja active Pending
- 2017-06-30 CA CA3025636A patent/CA3025636C/en active Active
- 2017-06-30 KR KR1020170083259A patent/KR102329162B1/ko active Active
- 2017-06-30 WO PCT/KR2017/006980 patent/WO2018004306A1/en not_active Ceased
- 2017-06-30 PE PE2018003174A patent/PE20190811A1/es unknown
- 2017-06-30 BR BR112018074621-5A patent/BR112018074621B1/pt active IP Right Grant
- 2017-06-30 PH PH1/2018/502507A patent/PH12018502507B1/en unknown
- 2017-06-30 CN CN202110351304.2A patent/CN113135920A/zh active Pending
- 2017-06-30 MX MX2018016287A patent/MX388591B/es unknown
- 2017-06-30 EP EP17820582.9A patent/EP3478687B1/en active Active
- 2017-06-30 CN CN201780039336.0A patent/CN109311896B/zh active Active
-
2018
- 2018-11-27 IL IL263306A patent/IL263306B/en active IP Right Grant
- 2018-11-28 SA SA518400547A patent/SA518400547B1/ar unknown
- 2018-11-28 SA SA521430937A patent/SA521430937B1/ar unknown
- 2018-12-07 CL CL2018003511A patent/CL2018003511A1/es unknown
- 2018-12-07 CO CONC2018/0013293A patent/CO2018013293A2/es unknown
- 2018-12-10 DO DO2018000275A patent/DOP2018000275A/es unknown
- 2018-12-13 ZA ZA2018/08431A patent/ZA201808431B/en unknown
- 2018-12-18 EC ECSENADI201893777A patent/ECSP18093777A/es unknown
-
2020
- 2020-06-04 JP JP2020097918A patent/JP7084961B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11339167B2 (en) | 2017-12-28 | 2022-05-24 | Daewoong Pharmaceutical Co., Ltd. | Substituted piperidines as kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003511A1 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa. | |
| CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| ECSP20035588A (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CL2018002759A1 (es) | Compuestos de pirrolotriazina como inhibidores de tam. | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| CR20150416A (es) | Inhibidores de cdc7 | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| PH12017501063A1 (en) | Compounds for the treatment of cancer |